Nasal and Ocular Immunization with Bacteriophage Virus-like Particle Vaccines Elicits Distinct Systemic and Mucosal Antibody Profiles
Vaccines · 03.08.2025 · 13 (8) · 829
DOI: 10.3390/vaccines13080829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 03.08.2025. Verfasst von Andzoa N Jamus und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics and Microbiology, School of Medicine, University of New Mexico, Albuquerque, NM 87131, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background/Objectives: Intramuscular immunization elicits systemic IgG and is the primary route of vaccine administration in humans. However, there is growing interest in utilizing other routes of administration to tailor antibody profiles, increase immunity at primary sites of infection, simplify administration, and eliminate needle waste. Here, we investigated the antibody profiles elicited by immunization with bacteriophage virus-like particle vaccine platforms at various routes of administration.
Methods
We chose two model bacteriophage vaccines for investigation: bacteriophage MS2 virus-like particles (VLPs) recombinantly displaying a short, conserved peptide from Chlamydia trachomatis major outer membrane protein (MS2) and bacteriophage Qβ VLPs displaying oxycodone through chemical conjugation (Qβ). We comprehensively characterized the antibodies elicited systemically and at various mucosal sites when the vaccines were administered intramuscularly, intranasally or periocularly with or without an intramuscular prime using various prime/boost schemes.
Results
Intranasal and periocular immunization elicited robust mucosal and systemic IgA responses for both MS2 and Qβ. The intramuscular prime followed by intranasal or periocular boosts elicited broad antibody responses, and increased antibodies titers at certain anatomical sites.
Conclusions
These findings demonstrate the tractability of bacteriophage VLP-based vaccines in generating specific antibody profiles based on the prime–boost regimen and route of administration.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Genetics and Microbiology, School of Medicine, University of New Mexico, Albuquerque, NM 87131, USA.
ORCID-Profile: Andzoa N Jamus, Zoe E R Wilton, Julian Flanagan, Isabella G Romano, Susan B Core
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- NIDA NIH HHS
- NIAID
- NIDA
- NCATS
- NCI
Zitieren
APA
Jamus, A. N., Wilton, Z. E. R., Armijo, S. D., Flanagan, J., Romano, I. G., Core, S. B., & Frietze, K. M. (2025). Nasal and Ocular Immunization with Bacteriophage Virus-like Particle Vaccines Elicits Distinct Systemic and Mucosal Antibody Profiles. Vaccines, 13(8), 829. https://doi.org/10.3390/vaccines13080829
Vancouver
Jamus AN, Wilton ZER, Armijo SD, Flanagan J, Romano IG, Core SB, et al. Nasal and Ocular Immunization with Bacteriophage Virus-like Particle Vaccines Elicits Distinct Systemic and Mucosal Antibody Profiles. Vaccines. 2025;13(8):829. doi:10.3390/vaccines13080829
BibTeX
@article{Jamus2025,
author = {Jamus, Andzoa N and Wilton, Zoe E R and Armijo, Samantha D and Flanagan, Julian and Romano, Isabella G and Core, Susan B and Frietze, Kathryn M},
title = {Nasal and Ocular Immunization with Bacteriophage Virus-like Particle Vaccines Elicits Distinct Systemic and Mucosal Antibody Profiles},
journal = {Vaccines},
year = {2025},
volume = {13},
number = {8},
pages = {829},
doi = {10.3390/vaccines13080829}
}
EUVIMED